Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: LHX stock price vs BMY: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at BMY's multiple
Needs BMY P/E.
Implied fair value · at LHX's multiple
Needs LHX P/E.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Higher is better
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
16 period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
L3HARRIS TECHNOLOGIES, INC. · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
BRISTOL-MYERS SQUIBB COMPANY · implied price per share
Bear
$50.67
Base
$61.69
Bull
$77.14
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
LOCKHEED MARTIN CORP
LHX vs LMT
NORTHROP GRUMMAN CORP /DE/
LHX vs NOC
BOEING CO
LHX vs BA
RTX Corp
LHX vs RTX
GENERAL DYNAMICS CORP
LHX vs GD
HEICO CORP
LHX vs HEI
Pfizer Inc.
LHX vs PFE
Merck & Co., Inc.
LHX vs MRK
AbbVie Inc.
LHX vs ABBV
Eli Lilly and Company
LHX vs LLY
Amgen Inc.
LHX vs AMGN
Gilead Sciences, Inc.
LHX vs GILD
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe LHX's premium multiple is justified by its stronger growth and balance-sheet quality, then hold or accumulate selectively because the company has a 9/9 Piotroski F-Score and lower leverage than BMY; otherwise, the valuation gap versus BMY and the DCF range argues for caution.
LHX trades at a clear premium to BMY-based implied value, with a current price of $302.07 versus implied price of $143.31, implying -52.6% downside. The gap is driven by LHX's much higher P/E and EV/EBITDA multiples than BMY, only partially offset by a slightly lower EV/Revenue multiple and stronger leverage profile.
Supporting Metrics
